Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results for Obstructive Hypertrophic Cardiomyopathy Drug

Investigational cardiac myosin inhibitor HRS-1893 shows potential as best-in-class treatment option with rapid and substantial reductions in left ventricular outflow tract gradient.

Mar. 30, 2026 at 2:06pm by Ben Kaplan

Got story updates? Submit your updates here. ›

Hengrui Pharma and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study found HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular outflow tract gradient (LVOT-G) with minimal change in left ventricular ejection fraction (LVEF) across dose groups.

Why it matters

HCM is among the most common rare diseases, affecting approximately 1 in 500 individuals in the United States. Two-thirds of patients with HCM have oHCM, where the thickened muscle creates a blockage in the heart's main pumping chamber, making it harder for blood to flow out to the body with each heartbeat. The positive Phase 2 results for HRS-1893 suggest it could become a novel, promising treatment option for this patient population with urgent needs.

The details

The 42-patient Phase 2 study found HRS-1893 treatment resulted in a range of complete Valsalva LVOT-G response (<30 mmHg) between 50% and 86%, with the range of LVEF decrease between 1.8% and 2.7%. HRS-1893 displayed rapid onset of effect, with the average Valsalva LVOT-G below 30 mmHg as early as day 5. The study found 89% of patients were well served at a 40 mg or 60 mg twice-daily dose regimen, with minimal to no titration required to achieve the target dose.

  • The multi-center, randomized, open-label Phase 2 dose-ranging study (NCT06516068) was conducted over 12 weeks.
  • At Week 39 of the open-label extension, the complete Valsalva LVOT-G response rate was 88%.

The players

Hengrui Pharma

An innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs.

Braveheart Bio

A late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions.

HRS-1893

Also known as BHB-1893, an investigational next-generation cardiac myosin inhibitor engineered to improve heart performance in patients with HCM.

Got photos? Submit your photos here. ›

What they’re saying

“The results of this study build on the clinical data observed to date and reinforce BHB/HRS-1893's potential as a highly differentiated treatment option for patients with oHCM.”

— Sheng Qi, Executive Director and Head of Cardiovascular, Hengrui Pharma

“We believe these results are consistent with a best-in-class clinical profile, with the potential to become a novel, promising treatment option for patients with obstructive hypertrophic cardiomyopathy.”

— Travis Murdoch, Chief Executive Officer and President, Braveheart Bio

What’s next

Braveheart Bio plans to initiate a global pivotal clinical study for HRS-1893 in 2026.

The takeaway

The positive Phase 2 results for HRS-1893 suggest it could become a novel, promising treatment option for patients with obstructive hypertrophic cardiomyopathy, a rare and serious heart condition that significantly limits patients' quality of life.